About lazertinib mesylate monohydrate
EGFR tyrosine kinase inhibitor
Used for
- Treats adults with advanced non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations, alongside amivantamab.
Usual adult dose
240 mg by mouth once daily, with amivantamab, until disease progression or unacceptable toxicity.
Common side effects
- Rash
- Nail inflammation
- Diarrhea
- Blood clots
Important warnings
- Can cause serious blood clots, including deep vein thrombosis and pulmonary embolism.
- Can cause lung inflammation; new or worsening breathing symptoms require urgent evaluation.
- May cause eye problems, severe skin reactions, or liver injury.
- Monitor blood counts, liver tests, and symptoms of bleeding or clotting.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for three weeks after the last dose.
Breastfeeding
Do not breastfeed during treatment and for three weeks after the last dose.
Interactions
- Strong or moderate CYP3A inducers may lower lazertinib levels and reduce effectiveness.
- Lazertinib may raise levels of certain P-glycoprotein or BCRP substrate medicines.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.